OBJECTIVES: We examined the association between candidate single nucleotide polymorphisms (SNPs) and disease activity in RA patients on MTX. METHODS: Our population was drawn from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study (BRASS), a prospective, observational cohort of RA patients. A total of 556 participants were genotyped using the Affymetrix 100K platform. Two hundred and sixty-two participants were on MTX therapy, including 120 on MTX monotherapy. The primary outcome was the disease activity score in 28 joints (DAS28-CRP). High disease activity was defined as DAS28-CRP >3.2. Low disease activity was defined as DAS28-CRP < or =3.2. We studied three candidate alleles in the ATIC, ITPA and MTHFR genes for association with DAS28-CRP. RESULTS: Among participants on MTX monotherapy, those carrying the minor allele of ATIC SNP rs4673993 were more likely to have low disease activity (P = 0.01). None of the other SNPs was associated with disease activity. Among patients on any MTX (combination or monotherapy), the minor allele of ATIC rs4673993 was also associated with low disease activity (P = 0.04). CONCLUSIONS: In this cross-sectional analysis, ATIC SNP rs4673993 was associated with low disease activity in patients on MTX. Further studies are needed to clarify the relationship between ATIC polymorphisms, disease activity and treatment response.
OBJECTIVES: We examined the association between candidate single nucleotide polymorphisms (SNPs) and disease activity in RApatients on MTX. METHODS: Our population was drawn from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study (BRASS), a prospective, observational cohort of RApatients. A total of 556 participants were genotyped using the Affymetrix 100K platform. Two hundred and sixty-two participants were on MTX therapy, including 120 on MTX monotherapy. The primary outcome was the disease activity score in 28 joints (DAS28-CRP). High disease activity was defined as DAS28-CRP >3.2. Low disease activity was defined as DAS28-CRP < or =3.2. We studied three candidate alleles in the ATIC, ITPA and MTHFR genes for association with DAS28-CRP. RESULTS: Among participants on MTX monotherapy, those carrying the minor allele of ATIC SNP rs4673993 were more likely to have low disease activity (P = 0.01). None of the other SNPs was associated with disease activity. Among patients on any MTX (combination or monotherapy), the minor allele of ATICrs4673993 was also associated with low disease activity (P = 0.04). CONCLUSIONS: In this cross-sectional analysis, ATIC SNP rs4673993 was associated with low disease activity in patients on MTX. Further studies are needed to clarify the relationship between ATIC polymorphisms, disease activity and treatment response.
Authors: Judith A M Wessels; Jeska K de Vries-Bouwstra; Bas T Heijmans; P Eline Slagboom; Yvonne P M Goekoop-Ruiterman; Cornelia F Allaart; Pit J S M Kerstens; Derkjen van Zeben; Ferdinand C Breedveld; Ben A C Dijkmans; Tom W J Huizinga; Henk-Jan Guchelaar Journal: Arthritis Rheum Date: 2006-04
Authors: Martina Fabris; Barbara Tolusso; Emma Di Poi; Roberta Assaloni; Luigi Sinigaglia; Gianfranco Ferraccioli Journal: J Rheumatol Date: 2002-09 Impact factor: 4.666
Authors: Linda E Kelemen; Thomas A Sellers; Joellen M Schildkraut; Julie M Cunningham; Robert A Vierkant; V Shane Pankratz; Zachary S Fredericksen; Madhura K Gadre; David N Rider; Mark Liebow; Ellen L Goode Journal: Cancer Res Date: 2008-04-01 Impact factor: 12.701
Authors: Martijn Verheus; James D McKay; Rudolf Kaaks; Federico Canzian; Carine Biessy; Mattias Johansson; Diederick E Grobbee; Petra H M Peeters; Carla H van Gils Journal: Breast Cancer Res Treat Date: 2007-12-07 Impact factor: 4.872
Authors: M E Weinblatt; H Kaplan; B F Germain; S Block; S D Solomon; R C Merriman; F Wolfe; B Wall; L Anderson; E Gall Journal: Arthritis Rheum Date: 1994-10
Authors: Laure Dossus; James D McKay; Federico Canzian; Stefan Wilkening; Sabina Rinaldi; Carine Biessy; Anja Olsen; Anne Tjønneland; Marianne U Jakobsen; Kim Overvad; Françoise Clavel-Chapelon; Marie-Christine Boutron-Ruault; Agnes Fournier; Jakob Linseisen; Annekatrin Lukanova; Heiner Boeing; Eva Fisher; Antonia Trichopoulou; Christina Georgila; Dimitrios Trichopoulos; Domenico Palli; Vittorio Krogh; Rosario Tumino; Paolo Vineis; José Ramon Quirós; Núria Sala; Carmen Martínez-García; Miren Dorronsoro; Maria-Dolores Chirlaque; Aurelio Barricarte; Fränzel J B van Duijnhoven; H B Bueno-de-Mesquita; Carla H van Gils; Petra H M Peeters; Göran Hallmans; Per Lenner; Sheila Bingham; Kay Tee Khaw; Tim J Key; Ruth C Travis; Pietro Ferrari; Mazda Jenab; Elio Riboli; Rudolf Kaaks Journal: Carcinogenesis Date: 2008-03-28 Impact factor: 4.944
Authors: Torben S Mikkelsen; Caroline F Thorn; Jun J Yang; Cornelia M Ulrich; Deborah French; Gianluigi Zaza; Henry M Dunnenberger; Sharon Marsh; Howard L McLeod; Kathy Giacomini; Mara L Becker; Roger Gaedigk; James Steven Leeder; Leo Kager; Mary V Relling; William Evans; Teri E Klein; Russ B Altman Journal: Pharmacogenet Genomics Date: 2011-10 Impact factor: 2.089
Authors: Anne Hinks; Halima Moncrieffe; Paul Martin; Simona Ursu; Sham Lal; Laura Kassoumeri; Tracey Weiler; David N Glass; Susan D Thompson; Lucy R Wedderburn; Wendy Thomson Journal: Ann Rheum Dis Date: 2011-04-22 Impact factor: 19.103
Authors: Karina I Halilova; Elizabeth E Brown; Sarah L Morgan; S Louis Bridges; Min-Ho Hwang; Donna K Arnett; Maria I Danila Journal: Int J Rheumatol Date: 2012-07-09